Latest
  • Original Article|Open Access

    Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

    Estefania Berge , Ana Arencibia , Elena Otón , Luis Cejas , Silvia Acosta , Francisco Pérez
    Aim: The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational retrospective study was conducted on 129 consecutive patients with compensated cirrhosis treated in 2015, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensations. Results: The median follow-up time was 16 months. Most patients were males (73%), the mean age was 58.1 years and the most frequent genotype was 1b (52.2%). All... Read more
    Hepatoma Res 2017;3:209-14. | doi:10.20517/2394-5079.2017.28
    Published on: 27 Sep 2017  | Viewed:126  | Downloaded:15
    +HTML| PDF
  • Case Report|Open Access

    Total regression of hepatocellular carcinoma bone metastases, after liver transplantation, with sorafenib-everolimus

    Dimitrios Giakoustidis , Athanasios Apostolos Gargavanis , Nikolaos Salveridis , Evangelos Cholongitas , Emmanouil Sinakos , Konstantinos Papapolychroniadis , Vasileios Papanikolaou
    Hepatocellular carcinoma (HCC) represents the 5th commonest malignancy worldwide. Liver transplantation consist a radical and most efficient treatment for HCC. Tumor recurrence or metastases after liver transplantation is not uncommon. Hereby is presented a case of a patient transplanted for alcoholic liver disease and HCC and presented with bone metastases a few months later. Treatment with sorafenib and everolimus showed full regression of the metastases. In conclusion, the point of this report is to advertise a single case of total regression of bone lesions due to HCC recurrence, with... Read more
    Hepatoma Res 2017;3:205-8. | doi:10.20517/2394-5079.2017.29
    Published on: 20 Sep 2017  | Viewed:175  | Downloaded:18
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Outcomes of emergency and interval hepatectomy for ruptured resectable hepatocellular carcinoma: a single tertiary referral centre experience

    Andrew Kai Yip Fung , Charing Ching Ning Chong , Kit Fai Lee , John Wong , Yue Sun Cheung , Anthony Kwong Wai Fong , Paul Bo San Lai
    Aim: The short and long term outcomes of patients who underwent emergency and interval hepatectomy for ruptured and resectable hepatocellular carcinoma (HCC) were analysed. Methods: The data of patients with ruptured HCC presenting between April 2004 and October 2015 were analysed. Emergency hepatectomy was defined as hepatectomy within 48 h of the clinico-radiological diagnosis of HCC rupture. Results: Thirty patients underwent hepatectomy for ruptured HCC. Nine (30%) patients underwent emergency hepatectomy. The median age was 56 and 54 years (P = 0.13) with a similar gender distribution.... Read more
    Hepatoma Res 2017;3:196-204. | doi:10.20517/2394-5079.2017.23
    Published on: 8 Sep 2017  | Viewed:367  | Downloaded:30
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Surgical strategy for huge and advanced hepatocellular carcinoma in Hong Kong

    Kenneth S.H. Chok
    In Hong Kong, surgical resection is the core curative treatment for huge and advanced hepatocellular carcinoma (HCC). For tumors measuring 10 cm or above, major hepatectomy is usually required, but a future liver remnant not large enough will preclude the operation. Hypertrophy of future liver remnant is a way to render more patients operable, and measures include portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy. For HCC that has invaded a major vessel, en bloc resection with immediate vessel reconstruction is necessary if thrombectomy... Read more
    Hepatoma Res 2017;3:189-95. | doi:10.20517/2394-5079.2017.33
    Published on: 3 Sep 2017  | Viewed:609  | Downloaded:45
    +HTML| PDF
  • Original Article|Open Access

    Transcatheter arterial chemoembolization in recurrent unresectable hepatocellular carcinoma after orthotopic liver transplantation

    Hasmukh J. Prajapati , Pavan Kavali , Hyun S. Kim
    Aim: To investigate the survivals and efficacy of the doxorubicin drug eluting beads transcatheter arterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) status post orthotopic liver transplantation. Methods: Consecutive patients with HCC who underwent orthotopic liver transplantation from 2005 to 2012 were reviewed. Patients who developed recurrent HCC after orthotopic liver transplantation and received doxorubicin drug eluting beads TACE therapy were identified and included in the study. Survivals were calculated from the time of 1st doxorubicin drug... Read more
    Hepatoma Res 2017;3:182-8. | doi:10.20517/2394-5079.2017.25
    Published on: 17 Aug 2017  | Viewed:321  | Downloaded:32
    +HTML| PDF
  • Case Report|Open Access

    Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

    Eman A. Rewisha , Maha M. Elsabaawy , Omar Elshaarawy , Ayat Abdullah , Dalia M. Elsabaawy , Omkolsoum M. Alhaddad
    Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy. Read more
    Hepatoma Res 2017;3:178-81. | doi:10.20517/2394-5079.2017.18
    Published on: 11 Aug 2017  | Viewed:928  | Downloaded:133
    +HTML| PDF
  • Original Article|Open Access

    Laparoscopic liver resection with lymph node dissection for gallbladder tumors suspected to be T1b/T2 carcinoma

    Masashi Isetani , Zenichi Morise , Akihiko Horiguchi
    Aim: The short-term perioperative results of laparoscopic treatment of gallbladder (GB) carcinoma were evaluated to determine whether this technique can be a feasible treatment option. Methods: Ten patients with fundus/body GB tumors (GBTs) underwent laparoscopic liver resection (LLR) and lymph node dissection. Additionally, 124 patients underwent LLR for liver tumors. These 124 LLRs included 79 partial resections (PRs), 11 left lateral sectionectomies (LLSs), 25 anatomical resections (ARs), and 9 small ARs (SARs). The operation time (OT), intraoperative blood loss (BL), and postoperative... Read more
    Hepatoma Res 2017;3:170-7. | doi:10.20517/2394-5079.2017.17
    Published on: 9 Aug 2017  | Viewed:458  | Downloaded:34
    +HTML| PDF
  • Topic: Advances in the diagnosis and treatment of liver fibrosis|Open Access

    Advances in the diagnosis and treatment of liver fibrosis

    Jenny Yeuk-Ki Cheng , Grace Lai-Hung Wong
    Liver fibrosis is the center of diagnosis and management of essentially all chronic liver diseases. While liver biopsy examination still has a role in diagnosis and drug development, it is replaced by non-invasive assessments of liver biopsy in majority of the clinical scenarios. Radiological approaches, namely transient elastography, acoustic radiation force impulse imaging, shear wave elastography, magnetic resonance elastography provide accurate diagnosis of advanced fibrosis and cirrhosis. Serum test formulae based on common laboratory parameters or more specialized parameters including... Read more
    Hepatoma Res 2017;3:156-69. | doi:10.20517/2394-5079.2017.27
    Published on: 8 Aug 2017  | Viewed:2321  | Downloaded:160
    +HTML| PDF
  • Original Article|Open Access

    In vitro antitumor efficacy of Kochia indica extract on human hepatocellular carcinoma cell line with or without 5-fluorouracil

    Nabil Mohie Abdel-Hamid , Ghada A. Tabl , Yousry E. El-Bolkiny , Walaa O. Zeina
    Aim: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the sixth most common cancer worldwide. The resistance to chemotherapy is a major obstacle in the treatment of HCC, necessitating the discovery of additional agents. There is a growing use of anticancer complementary and alternative medicine worldwide. Therefore, the aim of present study was focused on the confirmation of the suitability and validity of the new markers which would be achieved by demonstrating their significant change and reproducible expression during disease and disease management. Methods:... Read more
    Hepatoma Res 2017;3:149-55. | doi:10.20517/2394-5079.2016.50
    Published on: 21 Jul 2017  | Viewed:1901  | Downloaded:49
    +HTML| PDF
  • Original Article|Open Access

    Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

    Glenn W. Stambo , Deborah Cragan
    Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results: Nine of the 11 (81.8%) doxorubicin treated HCC... Read more
    Hepatoma Res 2017;3:141-8. | doi:10.20517/2394-5079.2017.12
    Published on: 12 Jul 2017  | Viewed:432  | Downloaded:65
    +HTML| PDF
  • Review|Open Access

    Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

    Man Zhu , Yan-Min Zhang
    Hepatocellular carcinoma (HCC) remains a challenging disease with a high recurrence rate after surgery and there is an imminent need to identify new treatments. Currently, adjuvant therapy like chemotherapeutics arises to counteract the malignant trait escaping from apoptosis of tumors induced by overexpressed anti-apoptotic factors in HCC. Myeloid cell leukaemia-1 (Mcl-1) as an anti-apoptotic member of Bcl-2 is highly expressed in diverse human cancers, which contributes to cancer cell survival and the resistance to diverse chemotherapeutic agents. It is confirmed that Mcl-1 protein... Read more
    Hepatoma Res 2017;3:129-40. | doi:10.20517/2394-5079.2017.14
    Published on: 6 Jul 2017  | Viewed:521  | Downloaded:64
    +HTML| PDF
  • Original Article|Open Access

    Use of gadobenate dimeglumine dynamic MRI for detection of early hepatocellular carcinoma in atypical hepatic focal lesions

    Mohamed F. El-Gazzar , Mohamed Ahmed Samy Kohla , Mahmoud M. El-Sakhawy , Mohamed M. Husseiny , Reda R. H. Yousef , Safinaz H. El-Shorbagy
    Aim: Gadobenate dimeglumine (multihance) is a contrast medium which can be used not only as an extracellular contrast agent for dynamic imaging of the liver, but also as a liver specific agent for the acquisition of hepatobiliary-phase images which are more helpful in evaluation of small atypical hepatic focal lesions equal or less than 3 cm. The authors tried to evaluate multihance dynamic magnetic resonance imaging (MRI) as a new modality in early detection of hepatocellular carcinoma (HCC). Methods: Thirty cirrhotic patients with small hepatic focal lesions (less than 3 cm in diameter),... Read more
    Hepatoma Res 2017;3:123-8. | doi:10.20517/2394-5079.2017.08
    Published on: 26 Jun 2017  | Viewed:951  | Downloaded:84
    +HTML| PDF
  • Review|Open Access

    Management of advanced hepatocellular carcinoma: review of current and potential therapies

    Asmaa Gomaa , Imam Waked
    Over the past few years, despite improvement in screening and diagnosis of hepatocellular carcinoma (HCC), advanced stage remains the most common presentation at diagnosis, with limited management options, especially options available to patients in limited resource countries. There is currently no effective systemic chemotherapy, targeted, or immunologic therapy for advanced stage HCC. Sorafenib is the only approved front-line molecular-targeted treatment,with slight survival benefit. Regorafenib has recently been approved as second line therapy for HCC after failure of sorafenib. Ongoing... Read more
    Hepatoma Res 2017;3:112-22. | doi:10.20517/2394-5079.2017.03
    Published on: 15 Jun 2017  | Viewed:2679  | Downloaded:415
    +HTML| PDF
  • Review|Open Access

    Roles of p53 in extrinsic factor-induced liver carcinogenesis

    Tim Link , Tomoo Iwakuma
    Liver cancer remains one of the most common human cancers with a high mortality rate. Therapies for hepatocellular carcinoma (HCC) remain ineffective, due to the heterogeneity of HCC with regard to both the etiology and mutation spectrum, as well as its chemotherapy resistant nature; thus surgical resection and liver transplantation remain the gold standard of patient care. The most common etiologies of HCC are extrinsic factors. Humans have multiple defense mechanisms against extrinsic factor-induced carcinogenesis, of which tumor suppressors play crucial roles in preventing normal cells... Read more
    Hepatoma Res 2017;3:95-104. | doi:10.20517/2394-5079.2017.07
    Published on: 6 Jun 2017  | Viewed:860  | Downloaded:65
    +HTML| PDF
  • Original Article|Open Access

    Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma

    Hie-Won Hann , Surbhi Jain , Grace Park , Jamin D. Steffen , Wei Song , Ying-Hsiu Su
    Aim: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence... Read more
    Hepatoma Res 2017;3:105-11. | doi:10.20517/2394-5079.2017.15
    Published on: 6 Jun 2017  | Viewed:1158  | Downloaded:141
    +HTML| PDF
  • Case Report|Open Access

    First case report of inflammatory myofibroblastic tumor of peritoneal cavity in a living donor liver transplantation recipient

    Naganathan Selvakumar , Parul Saboti , Sumaid Kaul , Subash Gupta
    Post-transplantation malignancies are well known complications after liver transplantation. Certain malignancies are more common in pediatric recipients than adults. Inflammatory myofibroblastic tumors (IMTs) are reactive neoplasms with miniscule malignant potential. IMTs are more common after hematopoietic stem cell transplantation. However, there is 1 case reported in the literature after deceased donor liver transplantation. The authors describe a case of IMT after living donor liver transplantation. The patient was a 1-year-old girl who underwent living donor liver transplantation... Read more
    Hepatoma Res 2017;3:86-9. | doi:10.20517/2394-5079.2017.01
    Published on: 17 May 2017  | Viewed:402  | Downloaded:42
    +HTML| PDF
  • Editorial|Open Access

    Liver transplantation in acute-on-chronic liver failure

    Roger Williams
    Hepatoma Res 2017;3:90-4. | doi:10.20517/2394-5079.2017.13
    Published on: 17 May 2017  | Viewed:1148  | Downloaded:87
    +HTML| PDF
  • Original Article|Open Access

    MELD score and AST-to-platelet ratio index predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study

    Joy Sarkar , Thomas DeLeon , Linda L. Wong
    Aim: Liver transplantation (LT) is the most effective treatment for long-term survival from hepatocellular carcinoma (HCC); however, insufficient donors limit therapy. The authors sought to identify characteristics that predicted long-term survival after non-transplant therapies in patients with small HCC. Methods: In a database of 1,050 HCC patients, the authors identified those with single HCC ≤ 3.0 cm, who underwent hepatic resection (HR, n = 16), radiofrequency ablation (RFA, n = 55), or LT (n = 23) with 5-year follow-up. Overall survival (OS) and odds-ratios (OR) for survival after... Read more
    Hepatoma Res 2017;3:79-85. | doi:10.20517/2394-5079.2017.06
    Published on: 9 May 2017  | Viewed:886  | Downloaded:59
    +HTML| PDF
  • Minireview|Open Access

    Primary hepatic lymphoma: is it a disease entity?

    Fei Xiong , Yong-Song Guan
    It is now widely accepted that lymphoma is a cancer of the lymphatic cells in the immune system and a type of blood cancer that develops when T or B lymphocytes of the white blood cells display uncontrolled proliferation and cellular immortality. Currently, a number of authors have published case reports or case series in which these lesions are defined as primary hepatic lymphoma. This minireview discusses several aspects of the entity of primary hepatic lymphoma, especially the dilemmas in diagnosis. Read more
    Hepatoma Res 2017;3:73-8. | doi:10.20517/2394-5079.2017.02
    Published on: 9 May 2017  | Viewed:607  | Downloaded:48
    +HTML| PDF
  • Minireview|Open Access

    Updates on hepatorenal syndrome and strategies bridging to liver transplantation

    Chung Yeung Cheung , Kenneth S.H. Chok
    Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation remains the only definitive treatment for hepatorenal syndrome. Due to the scarcity of liver grafts, many patients die waiting. This review focuses on the different strategies to bridge patients to liver transplantation and to improve the postoperative outcome. Read more
    Hepatoma Res 2017;3:67-72. | doi:10.20517/2394-5079.2016.48
    Published on: 12 Apr 2017  | Viewed:3387  | Downloaded:363
    +HTML| PDF
Hepatoma Research Print ISSN: 2394-5079; Online ISSN: 2454-2520
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Partners
Copyright © 2017 OAE Publishing Inc. All Rights Reserved.